| | |
D.__"Health care practitioner" has the same meanings as in | | section 1711-C, subsection 1, paragraph F. |
|
| | | E.__"Health plan" means a health plan providing prescription | | drug coverage as authorized under the federal Medicare | | Prescription Drug, Improvement and Modernization Act of | | 2003, Public Law 108-173. |
|
| | | F.__"Individual" means a natural person who is the subject | | of prescription drug information. |
|
| | | G.__"Pharmacy benefits manager" has the same meaning as in | | section 2699, subsection 1, paragraph F. |
|
| | | H.__"Prescription drug information" means information | | concerning prescription drugs as defined in Title 32, | | section 13702, subsection 24 and includes prescription drug | | orders as defined in Title 32, section 13702, subsection 25. |
|
| | | I. "Prescription drug information intermediary" means a | | person or entity that communicates, facilitates or | | participates in the exchange of prescription drug | | information regarding an individual.__"Prescription drug | | information intermediary" includes, but is not limited to, a | | pharmacy benefits manager, a health plan and an electronic | | transmission intermediary. |
|
| | | 2.__Confidentiality of health care information.__A | | prescription drug information intermediary may not sell or | | exchange for value prescription drug information that identifies | | directly or indirectly the individual except if expressly | | permitted under section 1711-C, Title 24, Title 24-A or the | | federal Health Insurance Portability and Accountability Act of | | 1996, Public Law 104-191, as amended. |
|
| | | 3.__Enforcement.__A violation of this section is a violation | | of the Maine Unfair Trade Practices Act. |
|
| | | Sec. 2. 22 MRSA §2700-A, sub-§4, as enacted by PL 2005, c. 392, §1, is | | amended to read: |
|
| | | 4. Fees. Beginning April 1, 2006, each manufacturer of | | prescription drugs that are provided to Maine residents through | | the MaineCare program under section 3174-G or the elderly low- | | cost drug program under section 254 shall pay a fee of $1,000 per | calendar year to the department State. Fees collected under this | | subsection must be used to cover the cost of overseeing | | implementation of this section, including but not limited to | | maintaining links to publicly accessible websites to which |
|
|